Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l; sodium chloride, quantity: 6.02 g/l; potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

United States - English - NLM (National Library of Medicine)

hospira, inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea) - hetastarch 6 g in 100 ml

United States - English - NLM (National Library of Medicine)

aspen veterinary - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydrostarch™ act as a plasma volume substitute for the treatment and prophylaxis of hypovolemia in all species. it is not a substitute for red blood cells or coagulation factors in plasma. hydrostarch™ is contraindicated in patients with a known hypersensitivity to hydroxyethyl starch, fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure, renal failure with oliguria or anuria not related to hypovolemia, patients receiving dialysis treatment, severe hypernatremia or severe hyperchloremia and intracranial bleeding.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; hydroxyethyl starch 130/0.4, quantity: 60 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Kenya - English - Pharmacy and Poisons Board

pt sanbe farma jl. taman sari no. 10 bandung west java,indonesia - hydroxyethyl starch 200 infusion - infusion - hydroxyethyl starch/hest 30 g (molar substitution… - hydroxyethylstarch

United States - English - NLM (National Library of Medicine)

hospira, inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea) - hetastarch 6 g in 100 ml - hextend (6% hetastarch in lactated electrolyte injection) is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. do not use hes products, including hextend, unless adequate alternative treatment is unavailable.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - hetastarch 6 g in 100 ml - hespan® is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. the adjunctive use of hespan® in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. - do not use hes products, including hespan®, unless adequate alternative treatment is unavailable. hetastarch has been shown to have an embryocidal effect on new zealand rabbits when given intravenously over the entire organogenesis period in a daily dose 1/2 times the maximum recommended therapeutic human dose (1500 ml) and on bd rats when given intraperitoneally, from the 16th to the 21st day of pregnancy, in a daily dose 2.3 times the maximum recommended therapeutic human dose. when hetastarch was administered to new zealand rabbits, bd rats, and swiss mice with intravenous daily doses of 2 times, 1/3 times, and 1 times the m

United States - English - NLM (National Library of Medicine)

hospira, inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea) - 6% hetastarch in 0.9% sodium chloride injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. the adjunctive use of 6% hetastarch in 0.9% sodium chloride injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. do not use hes products, including 6% hetastarch in 0.9% sodium chloride injection, unless adequate alternative treatment is unavailable. hetastarch has been shown to have an embryocidal effect on new zealand rabbits when given intravenously over the entire organogenesis period in a daily dose 1/2 times the maximum recommended therapeutic human dose (1500 ml) and on bd rats when given intraperitoneally, from the 16th to the 21st day of pregnancy, in a daily dose 2.3 times the maximum recommended therapeutic human dose. when hetastarch was administered

Malta - English - Medicines Authority

fresenius kabi limited - poly(o-2-hydroxyethyl)starch; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium chloride - solution for infusion - poly(o-2-hydroxyethyl)starch 60 g; potassium chloride 0.3 g; magnesium chloride hexahydrate 0.3 g; sodium acetate trihydrate 4.63 g; sodium chloride 6.02 g - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - poly, hydroxyethyl, starch, potassium chloride, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium chloride - solution for infusion - sodium acetate trihydrate 4.63 g sodium chloride 6.02 g magnesium chloride hexahydrate 0.3 g poly(o-2-hydroxyethyl)starch 60 g potassium chloride 0.3 g - blood substitutes and perfusion solutions